Kisspeptin-10 vs Oxytocin

Kisspeptin-10

Kisspeptin is the product of the KISS1 gene acting on the receptor KISS1R (formerly GPR54). It sits upstream of the hypothalamic-pituitary-gonadal axis: it is the trigger for pulsatile GnRH release from the hypothalamus, and therefore for LH and FSH from the pituitary and testosterone or oestradiol downstream. The pathway was found because loss-of-function KISS1R mutations cause hypogonadotropic hypogonadism. That position upstream is the whole point of the compound and also the reason to be careful with it - it does not act locally, it moves an entire endocrine axis. Unusually for this dataset, the human data is real and well controlled. Research groups, notably Dhillo and colleagues at Imperial College London, have given kisspeptin-10 and the longer kisspeptin-54 to healthy men and women by intravenous bolus, intravenous infusion and subcutaneous injection and measured the LH response directly with timed blood draws; separate fMRI work has examined limbic responses to sexual and emotional stimuli. A bolus of roughly 0.3 nmol/kg of kisspeptin-10 - about 25 to 30 mcg for a 70 kg adult - raises LH within tens of minutes, and that is where the 25 mcg floor here comes from. The typical 50 mcg figure sits just above that research bolus. The 200 mcg ceiling reflects the upper end of what grey-market users report, not a dose with controlled support; nothing above the research bolus has been shown to give a better response. Two caveats matter more than the number. First, the response desensitises: continuous or very frequent exposure downregulates the GnRH response instead of amplifying it, which is why intermittent dosing is the rational pattern and why more is not better. The every-other-day default here reflects that, not a trial protocol. Second, all of the human work is acute. There is no approved kisspeptin product anywhere, no long-term safety data, and nothing published on what repeated self-administration does to the axis over months, which is why no cycle length is given. Clearance is fast - kisspeptin-10 is cleared within a few minutes and kisspeptin-54 in roughly half an hour - so no hourly half-life is listed. Sensitivity differs between men and women and, in women, across the menstrual cycle. Note also that a 10 mg vial is far larger than a single dose: even reconstituted in 5 mL, 50 mcg is about 2.5 units on a U-100 syringe, so accurate measurement needs care or a further dilution.

Oxytocin

Oxytocin is a nine-amino-acid posterior pituitary hormone and, unlike most compounds in this dataset, an approved medicine: Pitocin and Syntocinon are licensed for obstetric use, given by titrated intravenous infusion to induce or augment labour and by IV or IM injection to control postpartum bleeding. PREGNANCY IS A HARD CONTRAINDICATION HERE, AND NOT AS A PRECAUTION. Oxytocin's approved pharmacological action is to make the uterus contract. Taken off-label by someone who is or might be pregnant, it risks uterine hyperstimulation, fetal distress, miscarriage or preterm labour. Legitimate obstetric use happens in a hospital with continuous fetal and contraction monitoring and the ability to stop the infusion within minutes; none of that exists around a self-administered wellness dose. Do not use this if pregnancy is possible. THE OBSTETRIC LABEL DOSING IS NOT TRANSFERABLE TO THE RANGE ON THIS PAGE, and the two must never be mixed. The label is expressed in USP units and delivered as a continuous IV infusion titrated in milliunits per minute against uterine response, or as a bolus IM dose after delivery. That is a different route, a different unit, a different endpoint and a different setting. No obstetric figure was used to build the range below, and a label dose read in units must not be entered here as micrograms - the international standard is roughly 1.68 mcg of peptide per IU, so units and micrograms are not interchangeable numbers. This entry also omits the IV and IM routes on purpose: they are the approved obstetric routes and are not what this tool models. The range here comes only from the intranasal social-cognition literature, where acute single doses of roughly 16-40 IU have been used and 24 IU is the conventional research dose; converted at about 1.68 mcg per IU that is roughly 27-67 mcg, rounded to 25-70 mcg. That literature is acute, single-dose, and its replication record is contested; chronic self-administration has not been studied at all. There is no controlled human data for subcutaneous wellness dosing, so the subq route is listed because it is what grey-market users actually do, not because a dose has been established for it. Practical notes: a 10 mg vial is enormously more than any documented dose. Even reconstituted in 5 mL, a 40 mcg dose is about 2 units on a U-100 syringe, which is at the edge of what can be drawn accurately - the 10 mg presentation is really sized for making up a nasal spray rather than for single subcutaneous draws. Plasma half-life is a few minutes, so no hourly figure is listed. The scheduler stores this as daily only because that is the closest available slot; the effect is acute and short-lived and typical off-label use is per occasion, not a fixed daily course.